{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:48:07Z","timestamp":1793814487948,"version":"4.6.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":966,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health-related quality of life (HRQoL) in ATTR CM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Nordic PROACT study was a cross-sectional non-interventional study conducted in 12 cardiology hospital clinics across Norway, Sweden, Finland and Denmark. Men and women aged \u226518 years diagnosed with symptomatic ATTR CM were included. The investigator provided information on medical history, biomarkers, current treatment, co-morbidities and disease severity according to the New York Heart Association (NYHA) class and the National Amyloidosis Centre (NAC) staging. Patients completed the HRQoL questionnaires in the form of the Kansas City Cardiomyopathy Questionnaire (KCCQ), the EQ-5D-5L index with Visual Analog Scale (VAS), and the Major Depression Inventory (MDI). A total of 169 patients (mean \u00b1 SD age 77.7 \u00b1 6.2 years) were included. Ninety-two per cent were men. Seventy-six per cent had wildtype ATTR CM (ATTRwt CM) and 15% had a hereditary form of ATTR CM (ATTRv CM) while 9% were genetically unclassified. Most patients were in NYHA class II (54%) and NAC stage 1 (53%). Participation in randomized clinical trials (RCT) was noted in 58% of the patients. The 169 ATTR CM patients had a mean \u00b1 SD KCCQ score of 64.3 \u00b1 23.1 for total symptom score, 64.8 \u00b1 20.9 for overall summary score (OSS) and 65.1 \u00b1 21.5 for clinical summary score. The EQ-5D-5L total utility score was 0.8 \u00b1 0.2 and the EQ-5D-5L VAS score was 62.9 \u00b1 20.6. The vast majority (89%) did not report any signs of depression. Patients with ATTRv CM had a higher KCCQ OSS as compared with ATTRwt CM, while EQ-5D-5L utility score, EQ-5D-5L VAS and MDI were similar. Non-RCT participants had a poorer HRQoL as compared with RCT participants as reflected in lower KCCQ OSS and EQ-5D-5L VAS scores and a higher MDI score. Patients with higher NYHA classes and NAC disease stages had a poorer HRQoL as demonstrated by lower KCCQ and EQ-5D-5L scores and higher MDI scores. Correlation between KCCQ, EQ-5D-5L and MDI and the covariate NYHA class remained significant (P &amp;lt; 0.05) after adjusting for multiple testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>KCCQ scores were lower than previously reported for patients with other heart diseases of non-ATTR CM origin. The HRQoL measures correlated well to NYHA class and NAC disease stage. The prevalence of depression appeared to be low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14350","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:39:08Z","timestamp":1679463548000},"page":"1871-1882","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Health-Related Quality of Life Among Transthyretin Amyloid Cardiomyopathy Patients"],"prefix":"10.1093","volume":"10","author":[{"given":"Per","family":"Eldhagen","sequence":"first","affiliation":[{"name":"Department of Medicine, Karolinska Institute, Karolinska University Hospital , Solna ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Lehtonen","sequence":"additional","affiliation":[{"name":"Heart and Lung Center, Helsinki University Hospital , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Gude","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital , Rikshospitalet, Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bagger-Bahnsen","sequence":"additional","affiliation":[{"name":"Pfizer Denmark , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Vakevainen","sequence":"additional","affiliation":[{"name":"Pfizer Finland , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Pilgaard","sequence":"additional","affiliation":[{"name":"Pfizer Denmark , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Wedell-Wedellsborg","sequence":"additional","affiliation":[{"name":"WW Projects , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nordic PROACT study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"2026012114103829100_ehf214350-bib-0001","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114103829100_ehf214350-bib-0002","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","article-title":"Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers","volume":"7","author":"Stewart","year":"2018","journal-title":"Neurol Ther"},{"key":"2026012114103829100_ehf214350-bib-0003","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"key":"2026012114103829100_ehf214350-bib-0004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: position statement of the German cardiac society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0005","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2026012114103829100_ehf214350-bib-0006","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0007","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ehf2.13884","article-title":"Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review","volume":"9","author":"Bay","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012114103829100_ehf214350-bib-0008","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114103829100_ehf214350-bib-0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"key":"2026012114103829100_ehf214350-bib-0010","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0011","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS)","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114103829100_ehf214350-bib-0012","first-page":"253","volume-title":"Functional capacity and objective assessment. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels","author":"Criteria Committee of the New York Heart Association","year":"1994","edition":"9th ed."},{"key":"2026012114103829100_ehf214350-bib-0013","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012114103829100_ehf214350-bib-0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026012114103829100_ehf214350-bib-0015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114103829100_ehf214350-bib-0016","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.amjcard.2020.10.066","article-title":"Impact of Tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in transthyretin cardiomyopathy clinical trial)","volume":"141","author":"Hanna","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2026012114103829100_ehf214350-bib-0018","first-page":"1","article-title":"Amyloidosis from the patient perspective: the French daily impact of amyloidosis study","author":"Damy","year":"2022","journal-title":"Amyloid"},{"key":"2026012114103829100_ehf214350-bib-0019","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQoL: a new facility for the measurement of health-related quality of life","volume":"16","author":"Group, E","year":"1990","journal-title":"Health Policy"},{"key":"2026012114103829100_ehf214350-bib-0021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S0033291702006724","article-title":"The internal and external validity of the major depression inventory in measuring severity of depressive states","volume":"33","author":"Olsen","year":"2003","journal-title":"Psychol Med"},{"key":"2026012114103829100_ehf214350-bib-0022","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/08039489850149741","article-title":"Applicability and validity of the major depression inventory in patients with Parkinson's disease","volume":"52","author":"Bech","year":"1998","journal-title":"Nord J Psychiatry"},{"key":"2026012114103829100_ehf214350-bib-0023","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis - a clinical challenge","volume":"304","author":"Ladefoged","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0024","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"2026012114103829100_ehf214350-bib-0025","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001755","article-title":"Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden","volume":"8","author":"Lauppe","year":"2021","journal-title":"Open Heart"},{"key":"2026012114103829100_ehf214350-bib-0026","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012114103829100_ehf214350-bib-0027","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012114103829100_ehf214350-bib-0028","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/fca-2021-0095","article-title":"Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: a plain language summary","volume":"18","author":"Hanna","year":"2022","journal-title":"Future Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012114103829100_ehf214350-bib-0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017278","article-title":"Change of health-related quality of life over time and its association with patient outcomes in patients with heart failure","volume":"9","author":"Sepehrvand","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026012114103829100_ehf214350-bib-0031","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","article-title":"Health-related quality of life outcomes in PARADIGM-HF","volume":"10","author":"Lewis","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026012114103829100_ehf214350-bib-0032","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0033","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012114103829100_ehf214350-bib-0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychores.2017.01.003","article-title":"DenHeart: differences in physical and mental health across cardiac diagnoses at hospital discharge","volume":"94","author":"Berg","year":"2017","journal-title":"J Psychosom Res"},{"key":"2026012114103829100_ehf214350-bib-0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11136-021-02982-3","article-title":"Inequality and heterogeneity in health-related quality of life: findings based on a large sample of cross-sectional EQ-5D-5L data from the Swedish general population","volume":"31","author":"Teni","year":"2022","journal-title":"Qual Life Res"},{"key":"2026012114103829100_ehf214350-bib-0036","article-title":"Danish population health measured by the EQ-5D-5L","volume":"51","author":"Jensen","year":"2021","journal-title":"Scand J Public Health"},{"key":"2026012114103829100_ehf214350-bib-0037","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11136-021-02938-7","article-title":"Norwegian population norms for the EQ-5D-5L: results from a general population survey","volume":"31","author":"Garratt","year":"2022","journal-title":"Qual Life Res"},{"key":"2026012114103829100_ehf214350-bib-0038","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid"},{"key":"2026012114103829100_ehf214350-bib-0039","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ejhf.1865","article-title":"Depression and heart failure: the lonely comorbidity","volume":"22","author":"Sbolli","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114103829100_ehf214350-bib-0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/CLEP.S132913","article-title":"The criterion validity of the web-based major depression inventory when used on clinical suspicion of depression in primary care","volume":"9","author":"Nielsen","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2026012114103829100_ehf214350-bib-0041","first-page":"55","article-title":"Heart failure functional class associated with depression severity but not anxiety severity","volume":"32","author":"Celik","year":"2016","journal-title":"Acta Cardiol Sin"},{"key":"2026012114103829100_ehf214350-bib-0042","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.amjcard.2009.01.025","article-title":"Relation of depression to severity of illness in heart failure (from heart failure and a controlled trial investigating outcomes of exercise training [HF-ACTION])","volume":"103","author":"Gottlieb","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026012114103829100_ehf214350-bib-0043","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053216","article-title":"Quality of life and disease experience in patients with heart failure with reduced ejection fraction in Spain: a mixed-methods study","volume":"11","author":"Rubio","year":"2021","journal-title":"BMJ Open"},{"key":"2026012114103829100_ehf214350-bib-0044","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13696998.2021.2011301","article-title":"Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial","volume":"25","author":"Xie","year":"2022","journal-title":"J Med Econ"},{"key":"2026012114103829100_ehf214350-bib-0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12955-020-01604-9","article-title":"Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City cardiomyopathy questionnaire","volume":"18","author":"Capota","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2026012114103829100_ehf214350-bib-0046","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ehjqcco\/qcab048","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study","volume":"8","author":"Halvorsen","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14350","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1871\/65017893\/eschf_10_3_1871.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1871\/65017893\/eschf_10_3_1871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:11:55Z","timestamp":1769022715000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/1871\/8304708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,22]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14350","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"2022-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}